Introduction
Biological therapy has dramatically improved the treatment of patients with JIA. However, there is still a group of patients that shows a lack of clinical response to this treatment. The use of robust predictive markers of response to identify individuals who are likely to respond to etanercept may provide guidance in optimizing treatment strategies.
Objectives
To test the ability of MRP8/14 serum levels to differentiate between responders and non-responders to etanercept before start of treatment, and to correlate longitudinal follow-up of these markers with response to treatment.
Methods
Samples were collected from 71 JIA patients (43 polyarthritis (12 RF positive), 18 extendend oligoarthritis, 3 persistent oligoarthritis, 1 enthesitis related arthritis, 6 psoriatic arthritis) included in the Dutch Arthritis and Biologics in Children (ABC) Register treated with etanercept. The patients were categorized into responders (acrpedi≥50) (n = 55) and non-responders (acrpedi≤50) (n = 16) according to the acrpedi response criteria and Wallace criteria of disease activity. Serum concentrations of MRP8/14 complexes were measured by ELISA at start of etanercept and in 34 patients also after start of treatment. Non-parametric tests were used to analyse the data.
Results
Before initiation of etanercept treatment, responders showed significantly higher levels of MRP8/14 serum complexes compared to non-responders (p < 0.001). Univariate analysis showed no association between MRP8/14 and JIA disease activity (JADAS10) at baseline. In non-responders levels did not significantly change after initiation of treatment whereas levels decreased in responders (p < 0.001).
Conclusion
High levels of baseline serum MRP8/14 have prognostic value in predicting a subgroup of JIA patients who will respond well to etanercept treatment. Decrease of MRP8/ 14 after initiation of treatment is associated with response to treatment.
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